Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLENPIQ vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Cleansing of the colon as a preparation for colonoscopy in adults
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
Sodium picosulfate: terminal half-life 7.4 hours (clinically not relevant as action is colonic); magnesium oxide and citric acid produce bicarbonate; half-life not applicable for osmotic component
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Bisacodyl (picosulfate) is hydrolyzed by colonic bacteria to its active metabolite BHPM; magnesium citrate acts locally.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Primarily fecal (97–98%) as unchanged drug; negligible renal excretion (<2%)
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Sodium picosulfate: <5% bound to plasma proteins
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
Sodium picosulfate: Vd ~0.2 L/kg (confined mainly to extracellular fluid, low tissue penetration)
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Oral (sodium picosulfate): low systemic bioavailability (<10%) due to extensive first-pass activation in colon; magnesium citrate is a locally active osmotic agent with negligible systemic absorption
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-59 m L/min/m²: reduce total prucalopride dose to 5 mg (i.e., single administration only).
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild to moderate impairment (Child-Pugh A or B).
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
No specific dose adjustment required solely based on age. Consider renal function (e GFR) and overall frailty; use conservative dosing in elderly with renal impairment (see renal_adjustment).
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
WARNING: RISK OF SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. CLENPIQ can cause significant fluid and electrolyte shifts, which may lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment. Monitor and correct electrolytes before use in patients at risk.
None
Risk of fluid and electrolyte abnormalities,Cardiac arrhythmias due to electrolyte imbalance,Seizures associated with electrolyte abnormalities,Renal impairment,Mucosal ulceration,Use with caution in patients with impaired gag reflex, reflux, or aspiration risk,Colonic mucosal aphthous ulcerations
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,Ileus,Hypersensitivity to any component,Severe renal impairment (e GFR <30 m L/min/1.73m²)
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
Avoid solid food during bowel preparation. Only clear liquids (water, clear broth, black coffee/tea, clear fruit juices without pulp, gelatin, popsicles) are permitted. Do not consume milk, cream, or any dairy products. Avoid red or purple colored liquids that may be mistaken for blood during colonoscopy. Do not consume alcohol.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to pregnant rats during organogenesis at doses up to 1.2 times the human dose (based on body surface area) did not produce fetal harm. However, because animal studies are not always predictive of human response, CLENPIQ should be used during pregnancy only if clearly needed. During the first trimester, consider alternative bowel preparation to avoid any theoretical risk. In second and third trimesters, use only if potential benefit justifies potential risk to fetus.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Excretion in human milk unknown. M/P ratio not available. Because many drugs are excreted in human milk, caution should be exercised when CLENPIQ is administered to a nursing woman. Consider temporary discontinuation of breastfeeding during the 24-hour period after CLENPIQ administration.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
No dose adjustment recommendations available due to lack of pharmacokinetic studies in pregnancy. However, physiological changes in pregnancy (increased plasma volume, renal blood flow) may affect drug disposition; use lowest effective dose and ensure adequate hydration. No specific dose reduction recommended.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
CLENPIQ (sodium picosulfate, magnesium oxide, and citric acid) is a colonoscopy preparation. Ensure adequate hydration before, during, and after use. Common adverse effects include nausea, vomiting, and abdominal distension. Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min), gastrointestinal obstruction, ileus, or known hypersensitivity. Avoid use within 1 hour of antacids or medications that affect gastrointestinal motility.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Take CLENPIQ as a split-dose regimen: one bottle the evening before and one bottle the morning of the colonoscopy.,Do not take any other laxatives or bowel preparations concurrently.,Stay hydrated by drinking clear liquids before and after each dose.,Do not eat solid food during the preparation period; only clear liquids are allowed.,Common side effects include nausea, bloating, and abdominal cramps; contact your doctor if severe or persistent.,Avoid driving or operating machinery if you feel dizzy or lightheaded.,Inform your doctor of all medications, especially diuretics, ACE inhibitors, ARBs, NSAIDs, or any drugs affecting kidney function.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLENPIQ vs COLYTE, answered by our medical review team.
CLENPIQ is a Laxative that works by Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLENPIQ and COLYTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLENPIQ is: Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLENPIQ and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLENPIQ is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.